Amid a push to phase out animal testing, Charles River’s Steve Bulera notes that the implementation of alternative methods ...

Gilead will integrate Interius, the first biotech to push an in vivo CAR-T therapy into the clinic, into its cell therapy ...

Bavarian Nordic bolstered its cash reserves with a $160m sale of a priority review voucher in June 2025. The company has now ...

The FDA has granted approval for Ionis Pharmaceuticals’ Dawnzera (donidalorsen), for use in preventing hereditary angioedema ...

This webinar offers essential tools and insights to help organisations confidently navigate the BioSecure Act, ensuring they ...

Before Novo arrived as its owner, issues at the Bloomington facility caused a two-month delay for Eylea HD’s FDA approval ...

Tariff rates on generic pharmaceutical products imported from the EU to the US will now be “effectively zero or close to zero ...

Antibody‑drug conjugates (ADCs) remain an area of extreme focus in the pharmaceuticals space, with the market projected to ...

The upcoming Clinical Trials in Rare Diseases conference will cover the most concerning challenges in rare disease research.

Andelyn Biosciences has entered into a collaboration with Amplo Biotechnology for manufacturing AAV gene therapies.

Santen has signed an agreement with RemeGen for the RC28-E intravitreal injection, a dual-target fusion protein for retinal ...

The agreement with Palatin follows a $1bn deal with Re-Vana earlier this year as Boehringer targets the ophthalmology market.